Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PepsiCo

Philip Morris

Are these the best dividend stocks to buy today?

What Stocks to Buy Today? 3 Dividend Stocks To Watch After Earnings

AbbVie's Q4 earnings (ABBV) beat estimates, while sales miss the same. Full-year 2023 EPS falls short of estimates.

AbbVie (ABBV) Beats Q4 Earnings Estimates, Misses on Sales

AbbVie (ABBV) delivered earnings and revenue surprises of 1.69% and 1.52%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

AbbVie (ABBV) Q4 Earnings Beat Estimates

Generic competition will eat at Humira's roughly $20 billion in annual sales.

Do Humira Biosimilars Threaten AbbVie's Dividend?

AbbVie stock inched higher Thursday after the company reported mixed earnings and issued a light profit outlook. The post AbbVie Profit Outlook Widely Misses As The U.S. Humira Battle Kicks Off appeared first on Investor's Business Daily.

AbbVie Profit Outlook Widely Misses As The U.S. Humira Battle Kicks Off

AbbVie says international sales of Humira in the fourth quarter fell 26.5% from a year earlier.

AbbVie Posts an Earnings Beat but Forecast Misses as Competition Intensifies

Shares of AbbVie Inc. ABBV, -0.37% gained 2.4% in premarket trading on Thursday after the company beat earnings expectations for the fourth quarter of 2022. AbbVie had a profit of $2.4 billion, or $1.38 per share, in the fourth quarter of 2022, down from $4.0 billion, or $2.26 per share, in the same quarter in 2021.

AbbVie's stock gains on Q4 results

AbbVie Inc on Thursday forecast 2023 profit below Wall Street expectations, in the first outlook since its blockbuster arthritis drug Humira faced competition from cheaper biosimilars in the United States early this year.

AbbVie's 2023 profit forecast misses as Humira faces heat from rivals

Reports Full-Year Diluted EPS of $6.63 on a GAAP Basis, an Increase of 2.8 Percent; Adjusted Diluted EPS of $13.77, an Increase of 16.4 Percent; These Results Include an Unfavorable Impact of $0.39 Per Share related to 2022 Acquired IPR&D and Milestones Expense1 Delivers Full-Year Net Revenues of $58.054 Billion, an Increase of 3.3 Percent on a Reported Basis and 5.1 Percent on an Operational Basis Full-Year Global Net Revenues from the Immunology Portfolio Were $28.924 Billion, an Increase of 14.4 Percent on a Reported Basis, or 16.0 Percent on an Operational Basis.

AbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results

AbbVie's (ABBV) fourth-quarter performance is expected to reflect the impact of strong demand for immunology and neuroscience products.

Will AbbVie's (ABBV) New Drugs Continue to Drive Q4 Earnings?

Cameco

Canopy Growth

Under Armour

Shortly before noon Tuesday, the Dow Jones industrials traded 0.25% lower, while the S&P 500 was up 0.07% and the Nasdaq up 0.4%.

Earnings Previews: AbbVie, Cameco, Canopy Growth, PepsiCo, Under Armour

Blackstone Group

Citigroup

Cardinal Health

Cisco Systems

Devon Energy

Gilead Sciences

Altria

Pioneer Natural Resources

U.S. Bancorp

Verizon

Exxon Mobil

Hedge funds employ some of the world's brightest analysts, with the most resources for analyzing companies. Lists of the most widely owned blue-chips among hedge funds can be a good source of new investing ideas.

Hedge Funds Love These 8 Dividend Blue Chips, And So Should You

Align Technology

Baxter

BeiGene

Centene

Exact Sciences

GE HealthCare Technologies Inc

IDEXX Laboratories

Neurocrine Biosciences

Pfizer

After a sub-par performance in 2021, healthcare stocks outperformed the S&P 500 in 2022.

5 Best and Worst Performing Healthcare Stocks in January 2023

There is widespread concern about the impact of Humira biosimilars being available in the U.S. The consensus outlook is that ABBV's earnings will decline.

Wall Street Analysts And Options Market Suggest AbbVie Has Upside

AbbVie has seen its shares pull back in recent weeks. Humira has gone off patent in the US, but other assets are generating strong growth.

Is AbbVie A Buy Following The Share Price Slump?

Abbvie will lift a self-imposed $2 billion limit on acquisitions and mergers placed following a $63 billion deal for Botox maker Allergan in 2020 that shot up its debt, the company's chief executive officer told the Wall Street Journal.

Abbvie plans to lift $2 billion cap on deals - WSJ

Drugmaker is turning to next-generation successors to Humira to replenish billions of dollars in sales that will be lost, and lifting a self-imposed $2 billion limit on the size of deals it would do to add products.

AbbVie Aims for New Drugs to Boost Sales as Competitors Target Humira

The day has arrived: Biosimilars for the blockbuster drug Humira are now being sold in the US. AbbVie investors are rightfully apprehensive, although the company has prepared for this day for years.

AbbVie: The Dreaded Humira Cliff Is Here: Time To Sell?

Johnson & Johnson

These companies outperformed the market last year.

2 Stocks Down More Than 6% to Buy Right Now

Abbott Labs

All three belong to the elite group of stocks known as Dividend Kings.

3 Unstoppable Dividend Stocks to Buy in February

Amazon

Disney

Eli Lilly

NVIDIA

Tesla

UnitedHealth Group

The stock market finished January on a positive note. This is a good sign for investors, who incurred huge losses last year.

5 Best and Worst Performing Mega-Cap Stocks in January 2023

AbbVie has put in a mixed earnings performance, exceeding bottom line estimates in five consecutive quarters but falling short of sales expectations in each instance.

AbbVie Q4 Preview: What's in Store?

Mastercard

Good cash flows come to those who pick intelligently and wait.

If You Want Tons of Passive Income in the Future , Buy These 2 Stocks

Incyte

Both companies are performing better than the broader market over the past year.

2 Steady Stocks to Buy in a Recession

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for AbbVie Stock (ABBV)